Introducing First Human Data from Her-2 Targeting Agent ABY-271 Affibody Molecule

• Characterizing mechanisms of renal and hepatic injury associated with alpha-emitting radioligand therapies
• Evaluating clinical and molecular strategies to reduce off-target organ exposure and cumulative toxicity
• Guiding dosing, scheduling, and patient monitoring to enable safer clinical application of novel alpha emitters

Speakers: